Dianthus Therapeutics Inc. (DNTH) 近日公布了一项重要研发进展。针对其在研药物Claseprubart用于治疗慢性炎症性脱髓鞘性多发性神经病(CIDP)的三期临床试验(CAPTIVATE研究),公司已完成一项预设的中期应答者分析。基于该分析获得的积极数据,Dianthus Therapeutics已做出“提前推进”的决策,将继续推进该临床试验的进行。
Dianthus Therapeutics Inc. (DNTH) 近日公布了一项重要研发进展。针对其在研药物Claseprubart用于治疗慢性炎症性脱髓鞘性多发性神经病(CIDP)的三期临床试验(CAPTIVATE研究),公司已完成一项预设的中期应答者分析。基于该分析获得的积极数据,Dianthus Therapeutics已做出“提前推进”的决策,将继续推进该临床试验的进行。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.